The receptor binding domain (RBD) of the SARS-CoV-2 S protein had overall weaker antibody binding signals but, nevertheless, was significantly more reactive with COVID-19 patient serum IgG and IgA than with control serum IgG and IgA. This evidence concerns the gene PROS1 and COVID-19.